Process for producing pyridoxal 5-phosphate (PLP) and composition obtained thereby
A cell-free bioprocess using the DXP-independent pathway with specific enzymes addresses yield and cost challenges in PLP production, achieving high yields and productivity while minimizing metabolic interference and toxicity, suitable for biorefinery applications.
Patent Information
- Application Number
- PCT/BR2026/050204
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods for producing pyridoxal 5-phosphate (PLP), a form of vitamin B6, face challenges such as low yield, high cost, and metabolic imbalances due to toxic intermediates, particularly in fermentative processes, and chemical synthesis methods suffer from low selectivity and expensive resources.
A novel cell-free bioprocess using the deoxyxylulose 5-phosphate (DXP)-independent pathway with specific enzymes, including Phosphoketolase and Pyridoxal 5-phosphate synthase, leverages xylose as a substrate to achieve high yields and productivity, overcoming metabolic interference and toxicity issues.
The process achieves superior yields and productivities of PLP, exceeding previous reports, utilizing low-cost, abundant substrates and simplifying reaction control, with potential applications in biorefineries and value-added biomass utilization.
Smart Images

Figure BR2026050204_12112026_PF_FP_ABST
Abstract
Description
PRODUCTION PROCESS FOR PYRIDOXAL 5-PHOSPHATE (PLP) AND COMPOSITION OBTAINED THEREOF Technical Field of the Invention
[0001] The present invention describes a novel process for producing pyridoxal 5-phosphate (PLP), vitamin B6, with improved yield and productivity, as well as its related compositions. The invention is in the technical field of synthetic biochemistry. Background of the Invention
[0002] Vitamins are a group of essential nutrients needed to maintain normal metabolic activities and that act as coenzymes in physiological biochemical reactions. As isolated compounds, they can be used in food, cosmetics, animal feed, and medicines.
[0003] Among these, vitamin B6 is a fundamental nutrient involved in more human bodily processes than any other vitamin. However, humans are unable to synthesize it, and therefore this micronutrient must be obtained from food or through dietary supplements.
[0004] Currently, vitamin B6 can be produced through technological routes involving chemical or fermentative processes. In the case of chemical synthesis, vitamin B6 is obtained by a Diels-Alder reaction which, despite the high availability of starting materials (4-methyl-5-carboxyoxazole ester and butynediol), suffers from low to moderate selectivity, which impairs yields. Furthermore, it is a route with expensive and / or harmful resources. On the other hand, fermentative routes still struggle to produce high quantities of the final product due to the toxic characteristics of the intermediates formed during their biosynthesis. In addition, vitamin B6 interacts with a range of metabolic reactions, meaning that the accumulation of vitamin B6 inside the cell generates a metabolic imbalance.For these reasons, the highest concentration of vitamin B6 obtained by fermentation to date is 1.30 g / L, using the genetically modified microorganism Sinorhizobium meliloti IFO14782 / pVK611, in a 7-day process and employing a rather complex system.
[0005] The synthetic biochemistry approach has the potential to address cases where metabolic engineering faces highly complex challenges. By exploring a cell-free process, it is possible to minimize system complexity simply by mixing biocatalysts in a single reaction. While the cellular machinery of a genetically modified organism offers advantages in terms of self-sustaining cofactor supply (NADH, FADH, ATP, among others), it also limits the field of application due to complex regulatory systems and the vast network of interactions between metabolites. These interactions can create competition between biochemical pathways, redirecting carbon flow to undesirable routes. Because the cell-free approach works with a less complex system, carbon flow tends to be more easily directed to the final product.
[0006] There are two main reported pathways for the bioproduction of vitamin B6 in its active form, pyridoxal 5-phosphate (PLP). The most studied is the DXP-dependent pathway, present in some eubacteria. This pathway requires six enzymes and part of deoxyxylulose 5-phosphate (DXP), endose 4-phosphate, and glutamate to generate PLP. However, this pathway is unbalanced by cofactors and requires some additional enzymes and cofactors to start from simple monosaccharides such as glucose or xylose. On the other hand, the DXP-independent pathway requires seven enzymes and cofactors, but part of xylose, a simple sugar. Due to the versatility of cell-free metabolic engineering and by leveraging the natural catalytic repertoire of enzymes, it is possible to shorten the enzymatic cascade to six enzymes without the need for cofactor recycling.
[0007] Xylose plays a crucial role in the context of biorefineries and sustainable development. Sugarcane bagasse, an agro-industrial residue of extreme importance in Brazil and worldwide, contains approximately 20% xylose by its dry mass. Brazil alone has the potential to produce 162 million tons of this compound per year; therefore, the use of xylose presents enormous potential for application in the context of adding value to plant biomass.
[0008] In the search for the state of the art, the document containing technical content closest to that of the invention was patent application EP950715 (Enzymatic production of vitamin B6), which claims a process in which a cell-free extract comprising an enzymatic system is used for the conversion of 1-deoxy-D-threo-pentulose (DXP) and 4-hydroxy-L-threonine into vitamin B6. The enzymatic route presented in this patent application is independent of DXP. This means that different enzymes and substrates are used, in a process distinct from that proposed by document EP950715.
[0009] The document EP1543104 explored a microbiological approach by genetically modifying bacteria of the genus Rhizobium to produce vitamin B6. This document reveals a fermentation process using glucose as a building block. However, the microbiological approach still presents low production values (the highest production reported to date is 1.3 g / L). One of the main factors hindering production yield is the intermediates synthesized in the process, which are toxic to the cell, in addition to the ability of the final product to interact with a wide range of metabolic reactions.
[0010] Thus, this patent application presents a new bioprocess for the synthesis of vitamin B6, using low-cost, highly available substrates, and capable of generating yields and productivities that exceed the maximum reported to date. Based on the literature reviewed, no documents were found that anticipated or suggested the teachings of the present invention. Summary of the Invention
[0011] In this context, the present patent application presents a new process for the production of pyridoxal 5-phosphate (PLP), vitamin B6, via the deoxyxylulose 5-phosphate (DXP) pathway, independent of new enzymes, which allows for high yields of the final product in shorter times than those reported for prior art processes, especially those resulting from fermentative processes.
[0012] Thus, a new process for the production of pyridoxal 5-phosphate (PLP) via the deoxyxylulose 5-phosphate (DXP)-independent route is presented, comprising the use of: - 0.001 to 500 pg / mL of Phosphoketolase (XPK) with at least 90% identity to SEQID No. 3; and - 0.5 to 20 mg / mL of Pyridoxal 5-phosphate synthase (PdxS) with at least 90% identity to SEQID No. 6.
[0013] Additionally, a composition comprising Pyridoxal 5-Phosphate (PLP) is presented, wherein Pyridoxal 5-Phosphate (PLP) is produced according to the process defined herein in its general form or containing any of its particular embodiments and defined forms.
[0014] Furthermore, the present invention generates a low-carbon bioproduct using xylose as a building block. Since xylose is considered the second most abundant monosaccharide in biomass, the use of C5 sugar offers a promising alternative for the valorization of hemicellulose as well as for the development of technologies for the use of biomass in biorefineries. All the limitations of toxicity and metabolic interference found in in vivo processes (fermentative methods) are also overcome by the present process, generating a simpler process with greater control of reaction parameters, allowing for yields and productivities superior to the maximum reported in the prior art.
[0015] These and other objects of the invention will be immediately recognizable by those skilled in the art, and descriptions will be provided below in sufficient detail for their reproduction by a person skilled in the art. Brief Description of the Figures
[0016] In order to better define and clarify the content of this patent application, the following figures are presented:
[0017] Figure 1: Comparison between the two possible pathways for application in cell-free bioprocesses. (A) Although the literature reports a five-enzyme DXP-dependent pathway, if starting from simple sugars, it requires seven additional enzymes and glutamate as a sacrificial substrate. (B) Analysis of the maximum driving force for both pathways, considering physiological conditions (metabolite concentration less than 10 mM).
[0018] Figure 2: In silico model for the vitamin B6 cascade. The model determined the initial enzyme concentration based on kinetic parameters described in the literature. Abbreviations: G3P = Glyceraldehyde 3-phosphate, Xyl = Xylose, PLP = Pyridoxal 5-phosphate.
[0019] Figure 3. A: Xylose to 3-phosphoglycerate cascade for verification of xylose isomerase (XI), xylulokinase (XKS) and xylulose phosphoketolase (xpk2) activity. B. Absorbance at 340 nm, with activity only detectable in the presence of ATP.
[0020] Figure 4: Evaluation of the cascade proof of concept. (A) Standard curve of PLP made using the reaction mixture as a matrix. (B) Production of PLP using the initial conditions and enzymatic loading modeled in silico, including the Bs PdxS added histidine tail at the N-terminal portion, starting with 5 mM ATP and 20 mM xylose. The theoretical yield is 2.5 mM of PLP (calculated based on the limiting ATP).
[0021] Figure 5: Biochemical characterization of the LpXPK enzyme (SEQ ID No: 8) from the vitamin B6 cascade. The thermal tolerance assay was performed under proof-of-concept reaction conditions (37 °C and pH 8.0).
[0022] Figure 6: Melting curves (Tm) for Lp XPK (Activity at 37 °C of 0.01 U / mg and Tm=28 °C) and Pp XPK (Activity at 37 °C of 0.21 U / mg and Tm=63 °C).
[0023] Figure 7: PdxS activity and its respective denaturation temperatures.
[0024] Figure 8: Comparison of the vitamin B6 production kinetics of the initial and final sets of enzymes of the present invention, showing the increase in production due to the use of enzymes more compatible with the process.
[0025] Figure 9: Enzymatic cascade for vitamin B6 production with three ATP regeneration systems.
[0026] Figure 10: Ammonium sulfate tolerance test in the vitamin B6 cascade.
[0027] Figure 11: Different concentrations of Bc PdxS in the cascade. (A) PLP production profile over time. (B) Final PLP titers obtained for each concentration of Bc PdxS after 24 hours.
[0028] Figure 12: Comparison of cascades performed at 22 °C and 37 °C after 24 hours.
[0029] Figure 13: Graph of PLP production as a function of time comparing production in a synthetic medium using pure xylose against the industrially relevant medium using sugarcane bagasse hydrolysate as a xylose source. Using the conditions obtained in the synthetic medium, PLP production decreased by 64%, but after two steps of Plackett-Burmann hydrolysate optimization, the optimized hydrolysate was able to produce quantities similar to those obtained in the synthetic medium. Detailed Description of the Invention
[0030] This detailed description of the invention establishes some non-limiting definitions of the main terminologies and technical characteristics employed throughout this patent application, as well as providing examples of some embodiments of the present invention so that it can be reproduced by a person skilled in the art.
[0031] Thus, the present invention presents a process based on producing vitamin B6 from xylose via a synthetic biochemical pathway.
[0032] In one embodiment of the invention, the reaction is carried out at a temperature between 25 and 55 °C and at a pH between 6.5 and 9.5, and further comprises: - 0.5 to 1000 mM of Xylose; - 0.5 to 1000 mM of ammonium sulfate, where the amount of this component is equal to or greater than that of xylose; - 0.001 mM to 1 mM of Thiamine Pyrophosphate (TPP); - 0.01 mM to 100 mM of Magnesium Salt; - 0.5 to 1000 mM of polyphosphate, preferably sodium hexametaphosphate, wherein the amount of polyphosphate is equal to or greater than that of xylose; - 0.001 to 5 mg / mL of Xylose Isomerase (XI); - 0.001 to 5 mg / mL of Xylulokinase (XKS); - 0.01 to 5 mg / mL of ribulose 5-phosphate-3-epimerase (RPE); and - 0.01 to 5 mg / mL of ribulose 5-phosphate isomerase (RPI).
[0033] In one embodiment of the invention, the pH between 6.5 and 9.5 is maintained by tris buffer, potassium phosphate buffer (KPi), or a combination thereof.
[0034] In one embodiment of the invention, the reaction additionally comprises 0.1 to 1000 mM of ATP.
[0035] In one embodiment of the invention, the reaction further comprises 0.01 to 5.0 mg / mL of Polyphosphate kinase (PPK).
[0036] In one embodiment of the invention, the reaction is carried out in a single step.
[0037] In one embodiment of the invention, at least one of the previously defined enzymes is replaced by an enzyme of the same activity category and selected from at least one of the following options: - Xylose Isomerase (XI) where XI is SEQ ID No: 1; - Xylulokinase (XKS) where XKS is SEQ ID No: 2; - Ribulose 5-phosphate-3-epimerase (RPE) where RPE is SEQ ID No: 4; - Ribulose 5-phosphate isomerase (RPI) where RPI is SEQ ID No: 5; and - Polyphosphate kinase (PPK) where PPK is SEQ ID No: 7.
[0038] In one embodiment of the invention, the percentage of identity to at least one of the enzymes defined herein is at least 90%. In another embodiment of the invention, the percentage of identity to at least one of the enzymes defined herein is at least 95%.
[0039] In one embodiment of the invention, the present composition may be a pharmaceutical, nutraceutical, cosmetic and / or food supplement composition.
[0040] One embodiment of the invention may incorporate ATP recycling systems, changes in the ammonia donor, and the addition of the glutamine amidotransferase partner to PLP synthase.
[0041] In one embodiment of the invention, xylose is understood to mean synthetic and / or isolated xylose. Alternatively, in another embodiment of the invention, xylose is understood to mean xylose derived from lignocellulosic substrates, for example lignocellulosic hydrolysates.
[0042] Examples of implementation
[0043] The technology was developed using synthetic xylose and validated in sugarcane bagasse hydrolysate.
[0044] EXAMPLE 1: Initial in silico modeling
[0045] As already mentioned, two biological pathways from different substrates are described in the state of the art: DXP-dependent pathways and DXP-independent pathways.
[0046] The main technology exploits the deoxyxylulose 5-phosphate (DXP)-dependent pathway in a Sinorhizobium strain through a fermentative process. However, this pathway becomes complex with the synthetic biochemistry approach, since its redox potential is not balanced and the substrates are not abundant in nature. Furthermore, this pathway requires a glutamate molecule to provide the ammonia group, acting as a sacrificial substrate. That is, starting from simple sugars like glucose and fructose, seven additional enzymes would be needed, and even the cofactor remains unbalanced (Figure 1A, left).
[0047] On the other hand, the DXP-independent pathway requires only six enzymes (Figure 1 A, right). Starting with xylose as a substrate, a valuable alternative for lignocellulosic biomass is generated; and the ammonia group can be supplied directly from simple ammonium salts, e.g., ammonium sulfate. As these substrates are abundant and commercially viable, a system for this cascade was sought.
[0048] The second step requires ATP to phosphorylate xylulose into xylulose 5-phosphate (Xu5P). In this regard, xylulokinase from Thermotoga maritima (SEQ ID No: 2) is able to directly use polyphosphate to produce Xu5P. Thus, by applying this xylulokinase to the cascade, ATP would not be necessary. The second cofactor, thiamine pyrophosphate (TPP), does not need any recycling system because the TPP-dependent enzyme can regenerate TPP directly from solution, provided free phosphate is supplied. In this way, the overall cascade could operate without a regeneration system, using inexpensive inputs.
[0049] Furthermore, the maximum driving force (MDF) was analyzed for both pathways (Figure 1B). The MDF analysis evaluates the stoichiometry and thermodynamics of simple reactions and indicates whether it is likely to support a high flux through this pathway. The amino acid branch of the DXP-dependent pathway exhibits a favorable Gibbs free energy profile mainly due to the dehydration step of gluconate to 2-keto-3-deoxygluconate (-500.7 kJ / mol). On the other hand, the DXP branch faces a thermodynamic obstacle, demonstrated by the positive change in Gibbs free energy in the reduction and amination steps (Figure 1B). Although the DXP-dependent pathway presents a thermodynamically more favorable cascade, the DXP-independent pathway also presents an optimal Gibbs free energy profile, with the advantage of a more direct system.
[0050] The process was initially modeled in silico to determine the initial loading of enzymes and cofactors. Thus, enzymes already characterized and successfully expressed using the Escherichia coli system were prospected (Table 1).
[0051] Table 1. Enzyme screening for the vitamin cascade, showing the reaction conditions. Temperature Enzyme - Acronym Organism pH Cofactors at (°C) Xylose isomerase - ArXI Arachidicoc 6.8 37 Mg 2+ (SEQ ID No: 1) cus sp.Xylulokinase - TmXKS Thermotoga polyphosphate 6.2 45 (SEQ ID No: 2) marine o, Mg 2+ Xylulose-phosphoketolase - Lactiplantiba TPP, LpXpk cilus 6 37 Mg 2+ plantarum Ribulose 5-phosphate epimerase Bacillus - BmRPE methanolicu 7.7 30 Mn 2+ (SEQ ID No: 4) s Ribose 5-phosphate isomerase - Escherichia EcRPI 7.5 35 coli (SEQ ID No: 5) PLP Synthase - BsPdxS Bacillus 8 37 subtle
[0052] The initial model was built iteratively, adjusting important characteristics such as enzyme and cofactor concentrations in each round. The time course (Figure 2) revealed that the relative activities between the C3 and C5 branches are entirely dependent on the last step of the cascade (Figure 1A). This result was expected, since the C3 branch is composed of an irreversible reaction, transketolase, while the C5 branch presents two reversible reactions, isomerase and epimerase. Therefore, if the last step was not fast enough to prevent the accumulation of intermediates, the carbon flow would be redirected to the irreversible reaction, leading to the accumulation of glyceraldehyde 3-phosphate. Based on this, an initial enzyme concentration was defined to run the first batch for vitamin B6 production (Table 2).
[0053] Table 2. Initial conditions tested. Component Concentration TRIS Buffer pH 8.0 100 mM Ammonium sulfate 20 mM KPI buffer 20 mM Xylose 20 mM ATP or Polyphosphate 5 or 20mM Magnesium chloride 5 mM, Thiamine pyrophosphate 1 mM Sodium Chloride 250 mM Ar XI 0.2 mg / mL Tm XKS 0.2 mg / mL Lp XPK 0.001 mg / mL Bm EPR 0.5 mg / mL Ec RPI 0.5 mg / mL Bs PdxS 5.0 mg / mL
[0054] The proof-of-concept cascade, however, did not show vitamin B6 production even after 48 hours. Thus, it was found that at least one enzyme was not functioning under the reaction conditions (37°C and pH 8.0). To identify which step was not functioning, each enzyme involved in this system (Ar XI, Tm XKS, Lp Xpk, Bm RPE, Ec RPI, Bs PdxS) was characterized separately. Initially, the first half of the cascade, from xylose to glyceraldehyde 3-phosphate, was examined. If all these enzymes were active, the coupled reaction provided by non-phosphorylating glyceraldehyde 3-phosphate dehydrogenase (GapN) would be able to oxidize glyceraldehyde-3-phosphate to 3-phosphoglycerate at the cost of one NADP+ (Figure 3A). Under this particular condition, the xylulokinase from Thermotoga maritima (SEQ ID n° 2) could not directly utilize the polyphosphate to phosphorylate xylulose. Therefore, the addition of ATP was considered necessary.
[0055] The other enzymes were also tested separately. Of the six enzymes involved in the DXP-independent pathway, five had their activities verified, leaving only pyridoxal 5-phosphate synthase (BsPdxS). The synthase reaction was carried out for 12 hours using a commercial substrate (0.5 mM glyceraldehyde 3-phosphate, 0.5 mM ribose 5-phosphate, and 20 mM ammonium sulfate) with an excess of PLP synthase (5 mg / mL), but without any traces of PLP detected. Thus, the enzyme was investigated at the molecular level to better understand its inefficiency.
[0056] Although the production of this protein through expression via the pET21a plasmid is the state of the art, a plasmid that generates a histidine tail at the C-terminal portion, the addition of a stop codon after the open reading frame (ORF) and its removal are known. Therefore, two purification steps are necessary to obtain a pure PLP synthase. Since the in silico model showed a massive demand for this protein, it was decided to maintain the C-terminal histidine tail, as affinity chromatography is the most efficient and specific purification method. Analyzing the molecular structure of PLP synthase (PDB ID 2NV1), it is possible to identify the N-terminal portion on the surface. However, the C-terminal is a flexible loop that may be involved in the reaction mechanism.
[0057] To verify if the C-terminal HisTag was the cause of the lack of activity, the expression plasmid was altered to pET28a, generating an N-terminal HisTag. Since the initial BsPdxS gene had its stop codon removed, it was necessary to add it back via PCR. The restriction-digestion protocol was followed, using Ndel and Xhol enzymes, and cloning into pET28a. The sequences were traced by colony PCR and confirmed by sequencing. BsPdxS was expressed in a 1-liter culture of Escherichia coli BL21DE3 cells.
[0058] BsPdxS with the histidine tail in the N-terminal region was purified, and synthase activity was tested using the entire cascade, starting from xylose, ATP, and ammonium sulfate. The activity of all enzymes was confirmed, generating a yellow product in the reaction medium, as expected for the formation of a Schiff base between PLP and the primary amine of Tris. The increase in absorbance at 414 nm was monitored for 24 hours at 37°C (Figure 4).
[0059] XPK
[0060] In the vitamin B6 pathway, XPK is used to cleave xylulose 5-phosphate to form glyceraldehyde 3-phosphate and acetyl phosphate, at which point the cascade branches. Thermal shift assays demonstrated that the phosphoketolase from Lactoplantibacillus plantarum (LpXPK) is thermostable, with a melting point of 28°C. Although LpXPK is active at the cascade temperature (37°C), it completely loses activity after 1 hour (Figure 5). Searching the state-of-the-art enzyme databases, no thermostable phosphoketolase was found. Furthermore, no phosphoketolases from various thermophilic organisms were found in the inventors' known strain collection.
[0061] Thus, a new enzyme was tested and considered (Pp Xpk, SEQ ID n° 3), which has a melting point of 63°C. (figure 6).
[0062] PLP synthase - PdxS
[0063] The second bottleneck identified was the low activity of PLP synthase compared to the other enzymes in this cascade, with only 3,500 per mg of protein under the cascade conditions, accounting for 78% of the total protein dosage. However, according to enzyme databases, all enzymes exhibit activities ranging from 0.2 to 3.7 µm / mg, and a turnover number of 0.00017 to 0.004 s⁻¹. -1 Therefore, even if the synthase is not highly active, it can still remain active for longer, increasing the total turnover number (TTN).
[0064] Enzymatic characterizations of new PLP synthases were performed. The Bacillus coagulans homolog (Bc PdxS - SEQ ID No. 6) showed higher activity and thermal stability. Therefore, it was incorporated into the enzymatic cascade of the present invention, along with Pp Xpk (SEQ ID No. 3).
[0065] With a more active and heat-tolerant set of enzymes at hand, small-scale vitamin B6 production was carried out. After the first attempt at 100 pL reactions in microplates, the reactions were performed in 400 pL microcentrifuge tubes. Two cascades were performed under the same conditions, but applying the new phosphoketolase and PLP synthase (Lp Xpk x Pp Xpk and Bs PdxS x Bc PdxS - Figure 8). The final titers increased by 42.6% and 16.7% at 12 and 24 hours, respectively.
[0066] Optional addition of an ATP recycling system.
[0067] According to the in silico model, the accumulation of glyceraldehyde 3-phosphate may be the reason for the low yields, since the irreversible reaction is competing with the reversible ones. However, the results showed that the cascades accumulated only 0.34 ± 0.09 and 0.55 ± 0.04 mM of GA3P for the initial and optimized cascades, respectively. If all the GA3P were converted, it would be possible to achieve 58% of the theoretical yield. Therefore, it is possible to consider that another obstacle may be encountered before the production of xylulose 5-phosphate, since this intermediate is where the cascade branches (Figure 1A).
[0068] In light of this, three different recycling systems were proposed (Figure 9) to allow the cascade to function at lower ATP concentrations and to decrease the inhibitory effect on xylulokinase.
[0069] Recycling system 1 uses polyphosphatase kinase II from Ruegeria pomeroyi, regenerating ATP from polyphosphate. Polyphosphate is a low-cost phosphoryl donor easily produced by phosphoric acid dehydration or biological synthesis. System 2 utilizes the byproduct of phosphoketolase, acetyl phosphate, to produce acetate and ATP. However, only 0.5 mol of acetyl phosphate can be generated per mol of ATP consumed (Figure 9). The last system uses adenylate kinase from E. coli to utilize two phosphate molecules per ATP molecule.
[0070] Assembly of the entire PLP synthase complex and modification of the ammonia donor.
[0071] It is important to emphasize that ammoniacal nitrogen in solution exhibits ammonium-ammonia equilibrium (NH4). + = NH3 + H + ), with a pKa of 9.25. This means that under cascade conditions (pH 8.0), the ratio of NH4 +The concentration of NH3 is 17.7, suggesting that most of the ammoniacal nitrogen is in the form of ammonium. However, NH3 is the protonation state used by PLP synthase. Thus, directly calculating the amount of ammonia from ammonium sulfate may yield underestimated values. To ensure sufficient ammonia was supplied, we added 100 and 200 mM ammonium sulfate (Figure 10). The system showed a 33% decrease in yield, indicating the inhibitory effect of ammonium sulfate on the cascade, likely due to PLP synthase, which has been previously described as inhibited by high ammonia concentrations. Therefore, the cascade was maintained with 20 mM ammonium sulfate.
[0072] Bc PdxS Loading
[0073] According to in silico models, the last reaction catalyzed by Bc PdxS exhibits favorable thermodynamics (AG). 1 = -260.6 kJ / mol), and an equilibrium constant of 7.0 x 10 54It was observed that between 12 and 24 hours, PLP production rates decreased. To verify if it would be possible to increase the final PLP titers, a set of cascades was designed with Bc PdxS varying from 1 to 7 mg / mL. Considering the high enzyme demand for these tests, the reactions were reduced to 100 pL in microtiter plates. Although all in silico analyses did not show a thermodynamic barrier, an increase in PLP production was observed according to the concentration of Bc PdxS, suggesting a possible inhibition of the product for the PLP synthase enos, leading to the assumption that PLP synthase is the rate-limiting step of the cascade (Figure 11 A and B).
[0074] Next, the temperature was lowered from 37°C to room temperature (22°C - Figure 12). The results showed that PLP production was severely impaired, with a 50% decrease in vitamin production. Therefore, by lowering the reaction temperature, the final yields were also reduced.
[0075] Thus, from the initial 0.42 mM of vitamin B6 obtained in the first cascade under initial conditions by in silico modeling, it was possible to substantially increase the final result. The new phosphoketolase and PLP synthase had their activities improved 21 and 2 times, and the melting temperature increased by 35 and 13°C, respectively. Surprisingly, the alteration of these two enzymes improved the titers by 116% compared to the initial condition, reaching 0.87 mM in 12 hours. Furthermore, the yield and productivity obtained by this cascade were 35.1% and 18.1 mg L⁻¹, respectively. 1 h ' 1 , compared to 2.2% and 7.7 mg L⁻¹ 1 h ' 1 state of the art.
[0076] It was also found, based on the examples cited here, that by also altering the concentration of the cofactor (TPP) and its regeneration (PÜ4) 2 'free), production also improved by 80.9%.
[0077] Essay on sugarcane hydrolysis liquor
[0078] In order to evaluate the robustness of the developed technology, PLP production was tested on an industrially relevant substrate. As an example of this application, although not limited to these origins, hydrothermally pretreated sugarcane bagasse was used, subjected to enzymatic hydrolysis using the enzymatic cocktail as described at https: / / doi.org / 10.1186 / s13068-020-01732-w. This hydrolyzed liquor (0.167 mM xylose and 0.167 mM glucose) was used as a xylose source to initiate the enzymatic cascade. Using the same conditions obtained for synthetic xylose (100 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 10 mM potassium phosphate pH 8.0, 30 mM xylose from hydrolysate, 5 mM ATP, 5 mM magnesium chloride, 0.1 mg thiamine pyrophosphate, 0.2 mg mL⁻¹ 1 xylose isomerase, 0.2 mg mL 1 xylulokinase, 0.0025 mg mL 1 phosphoketolase, 0.5 mg / mL -1 ribose 5-phosphate epimerase, 0.5 mg mL -1ribulose 5-phosphate isomerase, 5 mg mL' 1 Using pyridoxal 5-phosphate synthase), a production of 0.31 mM of vitamin B6 was obtained after 12 hours. An optimization of the process variables for hydrolyzed sugarcane liquor was performed by Plackett-Burman (PB), with a total of 32 experiments. Within this set, 11 variables were evaluated, including the process enzymes according to the present invention, temperature, pH, ATP concentration, and substrate concentration, in 2 rounds of experiments (Tables 3 and 4).
[0079] Table 3. Experimental conditions of the first Plackett-Burman analysis. Condition ArXI TmXK PpXpk BmRP EcRPI BcPdx Temperat ATP pH Substrate mg SES ura mM to ml_" 1 mg rnUpg mUmg mL' mg mg ml_- °C mM 1 1 1 ml_- 1 1+1 0.35 0.35 5 0.9 0.9 6 42 8 8.5 50 0 0.2 0.2 2.55 0.5 0.5 5 37 5 8 30 -1 0.05 0.05 0.1 0.1 0.1 4 32 2 7.5 10 A +1 -1 -1 -1 +1 -1 -1 +1 +1 -1 B +1 +1 -1 -1 -1 +1 -1 -1 +1 +1 C +1 +1 +1 -1 -1 -1 +1 -1 -1 +1 D +1 +1 +1 +1 -1 -1 -1 +1 -1 -1 E -1 +1 +1 +1 +1 -1 -1 -1 +1 -1 F +1 -1 +1 +1 +1 +1 -1 -1 -1 +1 G -1 +1 -1 +1 +1 +1 +1 -1 -1 -1 H +1 -1 +1 -1 +1 +1 +1 +1 -1 -1 I +1 +1 -1 +1 -1 +1 +1 +1 +1 -1 J -1 +1 +1 -1 +1 -1 +1 +1 +1 +1 K -1 -1 +1 +1 -1 +1 -1 +1 +1 +1 L +1 -1 -1 +1 +1 -1 +1 -1 +1 +1 M -1 +1 -1 -1 +1 +1 -1 +1 -1 +1 N -1 -1 +1 -1 -1 +1 +1 -1 +1 -1 O -1 -1 -1 +1 -1 -1 +1 +1 -1 +1 P -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 Ponto 0 0 0 0 0 0 0 0 0 0 Central
[0080] Tabela 4. Condições experimentais para a segunda análise de Plackett Burman. Condiç ArXI TmXK PpXp BmRP EcRP BcPdx Temperat ATP pH SubstraTPP ão mg S k E I S ura to ml_’ 1 mg pg mg mg mg °C mM mM mM ml_’ 1 ml_’ 1 ml_’ 1 mb 1 mb 1 +1 0.35 - 5 - - 6 42 - 8.5 50 +1 0 0.2 - 2.55 - 0.5 5 37 5 8 - -1 -1 0.05 0.05 0.1 0.1 - 4 32 - 7.5 - -1 A +1 -1 -1 -1 0 -1 -1 0 -1 +1 +1 B +1 -1 -1 -1 0 +1 -1 0 -1 +1 -1C +1 -1 +1 -1 0 -1 -1 0 +1 +1 -1 D +1 -1 +1 -1 0 -1 +1 0 +1 +1 -1 E -1 -1 +1 -1 0 -1 +1 0 +1 +1 +1 F +1 -1 +1 -1 0 +1 +1 +1 G -1 -1 -1 -1 0 +1 +1 0 -1 +1 +1 H +1 -1 +1 -1 0 +1 -1 0 +1 +1 +1 I +1 -1 -1 -1 0 +1 +1 0 -1 +1 -1 J -1 -1 +1 -1 0 -1 -1 0 +1 +1 +1 K -1 -1 +1 -1 0 +1 +1 0 +1 +1 -1 L +1 -1 -1 -1 0 -1 +1 0 -1 +1 +1 M -1 -1 -1 -1 0 +1 -1 0 -1 +1 +1 N -1 -1 +1 -1 0 +1 -1 0 +1 +1 -1 O -1 -1 -1 -1 0 -1 +1 0 -1 +1 -1 P -1 -1 -1 -1 0 -1 -1 0 -1 +1 -1 Point 0 -1 0 -1 0 0 0 0 0 +1 0 Central
[0081] Of the 11 variables tested, three showed positive relationships (pH, temperature, and PpXpk), while one variable showed a negative relationship (BcPdxS). Therefore, for an optimized hydrolysate condition, the pH, temperature, and PpXpk concentration were increased to the upper limit used in PB analyses, while the BcPdxS concentration was tested at the lower limit. By making these changes, vitamin B6 production adopted a behavior similar to that obtained for synthetic xylose in the same time frame (Figure 13 - optimized hydrolysate), highlighting the robustness of the process. Thus, the optimized hydrolysate condition is shown in Table 3. The PLP value reached values around 0.80 mM.
[0082] Table 4. Experimental conditions for the hydrolysate optimized for PLP production. The reactions were carried out at 42 °C. Component Concentration TRIS Buffer pH 8.5 100 mM Ammonium sulfate 20 mM KPI buffer 20 mM Xylose 50 mM ATP 5 Magnesium chloride 5 mM Thiamine pyrophosphate 0.1 mM Sodium Chloride 250 mMZtrXI 0.05 mg / mL Tm XKS 0.05 mg / mL PpXPK 0.005 mg / mL Bm RPE 0.1 mg / mL Ec RPI 0.5 mg / mL Bs PdxS 4.0 mg / mL
[0083] The examples presented here are intended only to illustrate some of the numerous ways in which the present invention can be implemented and used, without limiting the interpretation of its scope and breadth, as well as any alternative forms and configurational variations thereof that will be defined based on the claims presented herein.
Claims
CLAIMS 1. Production process of Pyridoxal 5-Phosphate (PLP) via the Deoxyxylulose 5-phosphate (DXP)-independent route, characterized by comprising the use of: - 0.001 to 500 pg / mL of Phosphocetolase (XPK) as defined in SEQ ID no. 3; and - 0.5 to 20 mg / mL of Pyridoxal 5-phosphate synthase (PdxS) as defined in SEQ ID No.
6.
2. Process according to claim 1, characterized in that the reaction is carried out at a temperature between 25 and 55 °C and at a pH between 6.5 and 9.5 and further comprising: - 0.5 to 1000 mM of Xylose; - 0.5 to 1000 mM of ammonium sulfate, where the amount of this component is equal to or greater than that of xylose; - 0.001 mM to 1 mM of Thiamine Pyrophosphate (TPP); - 0.01 mM to 100 mM of Magnesium Salt; - 0.5 to 1000 mM of polyphosphate, preferably sodium hexametaphosphate, wherein the amount of polyphosphate is equal to or greater than that of xylose; - 0.001 to 5 mg / mL of Xylose Isomerase (XI); - 0.001 to 5 mg / mL of Xylulokinase (XKS); - 0.01 to 5 mg / mL of ribulose 5-phosphate-3-epimerase (RPE); and - 0.01 to 5 mg / mL of ribulose 5-phosphate isomerase (RPI).
3. Process according to claim 1, characterized in that the pH is maintained between 6.5 and 9.5 by tris buffer, potassium phosphate buffer (KPi) or a combination thereof.
4. Process according to claim 1, characterized by further comprising 0.1 to 1000 mM of ATP.
5. Process according to claim 4, characterized by further comprising 0.01 to 5.0 mg / mL of Polyphosphate kinase (PPK).
6. Process according to claim 1, characterized in that the reaction is carried out in a single step.
7. Process according to claim 1, 2 or 5, characterized in that at least one of the previously defined enzymes is replaced by an enzyme of the same activity category and selected from at least one of the following options: - Xylose Isomerase (XI) where XI is SEQ ID No: 1; - Xylulokinase (XKS) where XKS is SEQ ID No: 2; - Ribulose 5-phosphate-3-epimerase (RPE) where RPE is SEQ ID No: 4; - Ribulose 5-phosphate isomerase (RPI) where RPI is SEQ ID No: 5; and - Polyphosphate kinase (PPK) where PPK is SEQ ID No: 7 8. Process according to claim 1 or 7, characterized in that the percentage of identity of at least one of the enzymes is at least 90%.
9. Process according to claim 1 or 7, characterized in that the percentage of identity of at least one of the enzymes is at least 95%.
10. Composition comprising Pyridoxal 5-Phosphate (PLP) characterized in that Pyridoxal 5-Phosphate (PLP) is produced according to the process defined in any one of claims 1 to 9.
